The Relationship Between Stage of Diabetic Retinopathy and Retinal Blood Flow in Patients With IDDM During Euglycemic Clamp

Sponsor
Medical University of Vienna (Other)
Overall Status
Completed
CT.gov ID
NCT00814008
Collaborator
(none)
64
1
57
1.1

Study Details

Study Description

Brief Summary

Impaired retinal blood flow has been implicated in the pathogenesis of diabetic retinopathy. Patel et al. (1992) showed that retinal blood flow increases with the level of diabetic retinopathy. Grunwald et al. (1996) reported that patients with insulin dependent diabetes mellitus (IDDM) of relatively short duration have increased retinal blood flow, even before the onset of diabetic retinopathy. On the other hand the data of Bursell et al. (1996) indicate that IDDM patients have reduced retinal blood flow, when they have normal blood glucose levels, but this study may have considerable methodological limitations. Acute elevations of blood glucose levels, however, result in an increase in retinal blood flow (Grunwald et al. 1987, Bursell et al. 1996). Based on previous experimental data the investigators hypothesize that ocular blood flow is increased in early diabetes and reduced at later stages of the disease. Previous studies have demonstrated that metabolic conditions such as hyperglycemia influence outcome parameters and thereby might have confounded results regarding ocular blood flow in diabetic retinopathy. The investigators will therefore study patients with IDDM during euglycemic conditions.

Condition or Disease Intervention/Treatment Phase
Phase 2

Study Design

Study Type:
Interventional
Anticipated Enrollment :
64 participants
Allocation:
Non-Randomized
Intervention Model:
Parallel Assignment
Masking:
None (Open Label)
Primary Purpose:
Diagnostic
Official Title:
The Relationship Between Stage of Diabetic Retinopathy and Retinal Blood Flow in Patients With IDDM During Euglycemic Clamp
Study Start Date :
Mar 1, 1999
Actual Primary Completion Date :
Apr 1, 2000
Actual Study Completion Date :
Dec 1, 2003

Outcome Measures

Primary Outcome Measures

  1. retinal blood flow after 1 hour of insulin clamp [2 x 2 minutes]

Secondary Outcome Measures

  1. Mean blood velocities in ophthalmic artery, posterior ciliary arteries and central retinal artery after 1 hour of insulin clamp [2 x 10 minutes]

Eligibility Criteria

Criteria

Ages Eligible for Study:
19 Years and Older
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
Yes
Inclusion Criteria:
Patients with IDDM:
  • Age >= 19 years

  • Best corrected visual acuity >= 0.8

  • Ametropia < 6 dpt

Healthy control subjects:
  • Age and sex matched to the subjects in the patients group

  • Best corrected visual acuity >= 0.8

  • Ametropia < 6 dpt

Exclusion Criteria:
Any of the following will exclude a diabetic patient from the study:
  • Presence of intraocular pathology other than diabetic retinopathy (for example: cataract, glaucoma, ocular hypertension)

  • Hypertension (Systolic blood pressure > 160 mm Hg or diastolic blood pressure > 90 mm Hg)

  • Previous laser photocoagulation treatment

  • Pregnancy (in women)

Any of the following will exclude a healthy subject from the study:
  • Regular use of medication, abuse of alcoholic beverages, participation in a clinical trial in the 3 weeks preceding the study

  • Treatment in the previous 3 weeks with any drug

  • Symptoms of a clinically relevant illness in the 3 weeks before the first study day

  • History or presence of gastrointestinal, liver or kidney disease, or other conditions known to interfere with distribution, metabolism or excretion of study drugs

  • Blood donation during the previous 3 weeks

  • Pregnancy (in women)

Contacts and Locations

Locations

Site City State Country Postal Code
1 Department of Clinical Pharmacology, Medical University of Vienna Vienna Austria 1090

Sponsors and Collaborators

  • Medical University of Vienna

Investigators

  • Principal Investigator: Hans-Georg Eichler, MD, Department of Clinical Pharmacology, Medical University of Vienna

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
, ,
ClinicalTrials.gov Identifier:
NCT00814008
Other Study ID Numbers:
  • OPHT-181298
First Posted:
Dec 23, 2008
Last Update Posted:
Dec 23, 2008
Last Verified:
Dec 1, 2008
Additional relevant MeSH terms:

Study Results

No Results Posted as of Dec 23, 2008